1. Munoz-Davila MJ. Role of old antibiotics in the era of antibiotic resistance. highlighted nitrofurantoin for the treatment of lower urinary tract infections. Antibiotics 2014; 3:39–48.
2. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14:107–17.
5. Sharma D, Kumar D, Singh M, et al. Taste masking technologies: a novel approach for the improvement of organoleptic property of pharmaceutical active substance. IRJP 2012; 3(4):108–16.
7. Munira M, Sudha R, Swapan K. Taste masking techniques for bitter drugs – an overview. IJPT 2012; 4(2):2100–18.
8. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm 2004; 30(5):429–48.
9. MEDICAMENTA, l’atlante farmaceutico. Monografia “Nitrofurantoina”. Società Cooperativa Farmaceutica – Via Passione 8 – 20122 Milano, 2021.
10. Biosic M, Skoric I, Beganovic J, et al. Nitrofurantoin hydrolytic degradation in the environment. Chemosphere 2017; 186:660–8.
11. Jia C, Kim YS, Huang W, et al. Sensory and instrumental assessment of Chinese moon cake: Influences of almond flour, maltitol syrup, fat, and gums. Food Res Int 2008; 41(9):930–6.
12. Shayoub ME, Sami MA, Ali MS, et al. Evaluation of guar gum as suspension agent in comparison with xanthan gum using metronidazole benzoate as model of drug to estimate the effects of temperatures and storage on its suspension ability. J Global Biosci 2015; 4(6):2452–8.
13. Musko M, Sznitowska M. Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan. Acta Pharm 2014; 64:463–74.
14. Garcia-Ochoa F, Santos VE, Casas JA, et al. Xanthan gum: production, recovery, and properties. Biotechnol Adv 2000; 18:549–79.
15. Helin-Tanninen M, Autio K, Keski-Rahkonen P, et al. Comparison of six different suspension vehicles in compounding of oral extemporaneous nifedipine suspension for paediatric patients. EJHPharm 2012; 19(5):432–7.
16. Bilal S, Dabo I, Dewu B, et al. Refining and characterisation of gum arabic using vacuum filtration method for application in oil and gas drilling fluid formulation. JER 2015; 3(2):73–80.
17. Lopez CG, Rogers SE, Colby RH, et al. Structure of sodium carboxymethyl cellulose aqueous solutions: A SANS and rheology study. J Polym Sci B Polym Phys 2015; 53(7):492–501.
18. Karajgi S, Mali S. UV spectrophotometric area under curve method for the determination of nitrofurantoin in tablet formulations. IJRSR 2018; 9(1F):23293–6.
19. Parra GG, Ferreira LP, Codognato DCK, et al. Characteristics of the excited states of nitrofurantoin, an anti-inflammatory and photoactive nitrofuran derivative. J Lumin 2017; 185:10–6
20. EUROPEAN PHARMACOPOEIA 10.0. Nitrofurantoin, pp. 3375.
23. Ensom MHH, Decarie D. Stability of nitrofurantoin in extemporaneously compounded suspensions. Can J Hosp Pharm 2006; 59:29–33.
24. Biosic M, Skoric I, Beganovic J, et al. Nitrofurantoin hydrolytic degradation in the environment. Chemosphere 2017; 186:660–8.
25. Talukdar MM, Van den Mooter G, Augustijns P, et al. In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. Int J Pharm 1998; 169(1):105–13.
26. Lu MF, Woodward L, Borodkin S. Xanthan gum and alginate based controlled release theophylline formulations. Drug Dev Ind Pharm 1991; 17(14):1987–2004.
27. Dhopeshwarkar V, Zatz JL. Evaluation of xanthan gum in the preparation of sustained release matrix tablets. Drug Dev Ind Pharm 1993; 19(9):999–1017.
28. Remington: The Science and Practice of Pharmacy. 21st edition. The University of the Sciences in Philadelphia: Lippincott Williams&Wilkins; 2006, pp. 336.
29. Wijma RA, Hunter A, Koch BCP, et al. Review of the pharmacokinetic properties of nitrofurantoin and nitroxoline. J Antimicrob Chemother 2018; 73:2916–26.
DOI: 10.1016/j.jddst.2024.106578
